Ahmed Nermin S, Samec Marek, Liskova Alena, Kubatka Peter, Saso Luciano
Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, 11835, Egypt.
Department of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 03601, Martin, Slovakia.
Discov Oncol. 2021 May 27;12(1):17. doi: 10.1007/s12672-021-00411-y.
Tamoxifen is the gold standard drug for the treatment of breast cancer in pre and post-menopausal women. Its journey from a failing contraceptive to a blockbuster is an example of pharmaceutical innovation challenges. Tamoxifen has a wide range of pharmacological activities; a drug that was initially thought to work via a simple Estrogen receptor (ER) mechanism was proven to mediate its activity through several non-ER mechanisms. Here in we review the previous literature describing ER and non-ER targets of tamoxifen, we highlighted the overlooked connection between tamoxifen, tamoxifen apoptotic effects and oxidative stress.
他莫昔芬是治疗绝经前和绝经后女性乳腺癌的金标准药物。它从一种失败的避孕药发展成为一种畅销药,是药物创新挑战的一个例子。他莫昔芬具有广泛的药理活性;一种最初被认为通过简单的雌激素受体(ER)机制起作用的药物,后来被证明是通过几种非ER机制介导其活性的。在此,我们回顾了以往描述他莫昔芬的ER和非ER靶点的文献,强调了他莫昔芬、他莫昔芬的凋亡作用和氧化应激之间被忽视的联系。